Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.

O. N. Gofrit, A. Shapiro, D. Pode, A. Sidi, O. Nativ, Z. Leib, J. A. Witjes, A. G. van der Heijden, R. Naspro, R. Colombo

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

OBJECTIVES: To evaluate the effectiveness of combined local bladder hyperthermia and intravesical chemotherapy for the treatment of patients with high-grade (G3) superficial bladder cancer. METHODS: Patients with G3 bladder tumors (Stage Ta or T1) were treated with combined intravesical chemotherapy with mitomycin-C and local radiofrequency hyperthermia of the bladder wall. The patients were treated with either a prophylactic protocol (40 mg mitomycin-C) after complete transurethral resection of all tumors or with an ablative protocol (80 mg mitomycin-C) when visible tumor was seen on video-cystoscopy or bladder biopsies were positive for carcinoma in situ. RESULTS: Combined chemo-thermotherapy was administered to 52 patients with high-grade superficial bladder cancer (40 patients with Stage T1 tumor, 11 with Ta, and 3 with concomitant or isolated carcinoma in situ). At a median follow-up of 15.2 months (mean 23, range 6 to 90), no stage progression to T2 or disease-related mortality had occurred. The bladder preservation rate was 86.5%. The prophylactic protocol was administered to 24 patients. After a mean follow-up of 35.3 months, 15 patients (62.5%) were recurrence free. The bladder preservation rate was 95.8%. The ablative protocol was administered to 28 patients. Complete ablation of the tumor was accomplished in 21 patients (75%). After a mean follow-up of 20 months, 80.9% of these patients were recurrence free. The bladder preservation rate for the ablative group was 78.6%. CONCLUSIONS: Combined local bladder hyperthermia and intravesical chemotherapy has a beneficial prophylactic effect in patients with G3 superficial bladder cancer. Ablation of high-grade bladder tumors is feasible, achieving a complete response in about three quarters of the patients.

Original languageEnglish
Pages (from-to)466-471
Number of pages6
JournalUrology
Volume63
Issue number3
Publication statusPublished - Mar 2004

Fingerprint

Induced Hyperthermia
Urinary Bladder Neoplasms
Urinary Bladder
Drug Therapy
Mitomycin
Therapeutics
Carcinoma in Situ
Neoplasms
Recurrence
Cystoscopy

ASJC Scopus subject areas

  • Urology

Cite this

Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. / Gofrit, O. N.; Shapiro, A.; Pode, D.; Sidi, A.; Nativ, O.; Leib, Z.; Witjes, J. A.; van der Heijden, A. G.; Naspro, R.; Colombo, R.

In: Urology, Vol. 63, No. 3, 03.2004, p. 466-471.

Research output: Contribution to journalArticle

Gofrit, ON, Shapiro, A, Pode, D, Sidi, A, Nativ, O, Leib, Z, Witjes, JA, van der Heijden, AG, Naspro, R & Colombo, R 2004, 'Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.', Urology, vol. 63, no. 3, pp. 466-471.
Gofrit, O. N. ; Shapiro, A. ; Pode, D. ; Sidi, A. ; Nativ, O. ; Leib, Z. ; Witjes, J. A. ; van der Heijden, A. G. ; Naspro, R. ; Colombo, R. / Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. In: Urology. 2004 ; Vol. 63, No. 3. pp. 466-471.
@article{93b288e141654fca956e81f0b58cfee6,
title = "Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.",
abstract = "OBJECTIVES: To evaluate the effectiveness of combined local bladder hyperthermia and intravesical chemotherapy for the treatment of patients with high-grade (G3) superficial bladder cancer. METHODS: Patients with G3 bladder tumors (Stage Ta or T1) were treated with combined intravesical chemotherapy with mitomycin-C and local radiofrequency hyperthermia of the bladder wall. The patients were treated with either a prophylactic protocol (40 mg mitomycin-C) after complete transurethral resection of all tumors or with an ablative protocol (80 mg mitomycin-C) when visible tumor was seen on video-cystoscopy or bladder biopsies were positive for carcinoma in situ. RESULTS: Combined chemo-thermotherapy was administered to 52 patients with high-grade superficial bladder cancer (40 patients with Stage T1 tumor, 11 with Ta, and 3 with concomitant or isolated carcinoma in situ). At a median follow-up of 15.2 months (mean 23, range 6 to 90), no stage progression to T2 or disease-related mortality had occurred. The bladder preservation rate was 86.5{\%}. The prophylactic protocol was administered to 24 patients. After a mean follow-up of 35.3 months, 15 patients (62.5{\%}) were recurrence free. The bladder preservation rate was 95.8{\%}. The ablative protocol was administered to 28 patients. Complete ablation of the tumor was accomplished in 21 patients (75{\%}). After a mean follow-up of 20 months, 80.9{\%} of these patients were recurrence free. The bladder preservation rate for the ablative group was 78.6{\%}. CONCLUSIONS: Combined local bladder hyperthermia and intravesical chemotherapy has a beneficial prophylactic effect in patients with G3 superficial bladder cancer. Ablation of high-grade bladder tumors is feasible, achieving a complete response in about three quarters of the patients.",
author = "Gofrit, {O. N.} and A. Shapiro and D. Pode and A. Sidi and O. Nativ and Z. Leib and Witjes, {J. A.} and {van der Heijden}, {A. G.} and R. Naspro and R. Colombo",
year = "2004",
month = "3",
language = "English",
volume = "63",
pages = "466--471",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.

AU - Gofrit, O. N.

AU - Shapiro, A.

AU - Pode, D.

AU - Sidi, A.

AU - Nativ, O.

AU - Leib, Z.

AU - Witjes, J. A.

AU - van der Heijden, A. G.

AU - Naspro, R.

AU - Colombo, R.

PY - 2004/3

Y1 - 2004/3

N2 - OBJECTIVES: To evaluate the effectiveness of combined local bladder hyperthermia and intravesical chemotherapy for the treatment of patients with high-grade (G3) superficial bladder cancer. METHODS: Patients with G3 bladder tumors (Stage Ta or T1) were treated with combined intravesical chemotherapy with mitomycin-C and local radiofrequency hyperthermia of the bladder wall. The patients were treated with either a prophylactic protocol (40 mg mitomycin-C) after complete transurethral resection of all tumors or with an ablative protocol (80 mg mitomycin-C) when visible tumor was seen on video-cystoscopy or bladder biopsies were positive for carcinoma in situ. RESULTS: Combined chemo-thermotherapy was administered to 52 patients with high-grade superficial bladder cancer (40 patients with Stage T1 tumor, 11 with Ta, and 3 with concomitant or isolated carcinoma in situ). At a median follow-up of 15.2 months (mean 23, range 6 to 90), no stage progression to T2 or disease-related mortality had occurred. The bladder preservation rate was 86.5%. The prophylactic protocol was administered to 24 patients. After a mean follow-up of 35.3 months, 15 patients (62.5%) were recurrence free. The bladder preservation rate was 95.8%. The ablative protocol was administered to 28 patients. Complete ablation of the tumor was accomplished in 21 patients (75%). After a mean follow-up of 20 months, 80.9% of these patients were recurrence free. The bladder preservation rate for the ablative group was 78.6%. CONCLUSIONS: Combined local bladder hyperthermia and intravesical chemotherapy has a beneficial prophylactic effect in patients with G3 superficial bladder cancer. Ablation of high-grade bladder tumors is feasible, achieving a complete response in about three quarters of the patients.

AB - OBJECTIVES: To evaluate the effectiveness of combined local bladder hyperthermia and intravesical chemotherapy for the treatment of patients with high-grade (G3) superficial bladder cancer. METHODS: Patients with G3 bladder tumors (Stage Ta or T1) were treated with combined intravesical chemotherapy with mitomycin-C and local radiofrequency hyperthermia of the bladder wall. The patients were treated with either a prophylactic protocol (40 mg mitomycin-C) after complete transurethral resection of all tumors or with an ablative protocol (80 mg mitomycin-C) when visible tumor was seen on video-cystoscopy or bladder biopsies were positive for carcinoma in situ. RESULTS: Combined chemo-thermotherapy was administered to 52 patients with high-grade superficial bladder cancer (40 patients with Stage T1 tumor, 11 with Ta, and 3 with concomitant or isolated carcinoma in situ). At a median follow-up of 15.2 months (mean 23, range 6 to 90), no stage progression to T2 or disease-related mortality had occurred. The bladder preservation rate was 86.5%. The prophylactic protocol was administered to 24 patients. After a mean follow-up of 35.3 months, 15 patients (62.5%) were recurrence free. The bladder preservation rate was 95.8%. The ablative protocol was administered to 28 patients. Complete ablation of the tumor was accomplished in 21 patients (75%). After a mean follow-up of 20 months, 80.9% of these patients were recurrence free. The bladder preservation rate for the ablative group was 78.6%. CONCLUSIONS: Combined local bladder hyperthermia and intravesical chemotherapy has a beneficial prophylactic effect in patients with G3 superficial bladder cancer. Ablation of high-grade bladder tumors is feasible, achieving a complete response in about three quarters of the patients.

UR - http://www.scopus.com/inward/record.url?scp=2942683157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942683157&partnerID=8YFLogxK

M3 - Article

C2 - 15028439

AN - SCOPUS:2942683157

VL - 63

SP - 466

EP - 471

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -